119 related articles for article (PubMed ID: 36657269)
21. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
Astermark J; Buckner TW; Frenzel L; Hatswell AJ; You X; Liu H; Goodman E; Santos S; Hawes C; Hinds D; Klamroth R
Haemophilia; 2023 Jul; 29(4):1087-1094. PubMed ID: 37347645
[TBL] [Abstract][Full Text] [Related]
22. Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab.
Bou-Jaoudeh M; Mimoun A; Delignat S; Peyron I; Capdevila L; Daventure V; Deligne C; Dimitrov JD; Christophe OD; Denis CV; Lenting PJ; Proulle V; Lacroix-Desmazes S
J Thromb Haemost; 2023 Oct; 21(10):2776-2783. PubMed ID: 37473843
[TBL] [Abstract][Full Text] [Related]
23. Emicizumab for acquired haemophilia A: A case series.
Engelen MM; Vandesande J; De Bent J; Van Laer C; Labarque V; Jacquemin M; Peerlinck K; Hermans C; Verhamme P; Vanassche T
Haemophilia; 2023 Jul; 29(4):1049-1055. PubMed ID: 37276345
[TBL] [Abstract][Full Text] [Related]
24. Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021.
Abbattista M; Ciavarella A; Noone D; Peyvandi F
J Thromb Haemost; 2023 Mar; 21(3):546-552. PubMed ID: 36710195
[TBL] [Abstract][Full Text] [Related]
25. The role of emicizumab in acquired hemophilia A.
Poston J; Kruse-Jarres R
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):24-30. PubMed ID: 38066880
[TBL] [Abstract][Full Text] [Related]
26. Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single-institution experience.
Chen EC; Gibson W; Temoczko P; Connell NT; Handin R; Parnes AD
Haemophilia; 2023 Jan; 29(1):84-89. PubMed ID: 36163651
[TBL] [Abstract][Full Text] [Related]
27. Agreement between one stage and chromogenic assays in samples from patients receiving recombinant porcine FVIII (Obizur, Susoctocog-alfa).
Guy S; Bowyer AE; Shepherd MF; Maclean RM; Kitchen S
Int J Lab Hematol; 2024 Feb; 46(1):135-140. PubMed ID: 37799011
[TBL] [Abstract][Full Text] [Related]
28. A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors.
Escobar M; Bullano M; Mokdad AG; Caicedo J; Schultz BG; Fan Q; Verma S
Expert Rev Hematol; 2023 Jun; 16(6):467-474. PubMed ID: 37114481
[TBL] [Abstract][Full Text] [Related]
29. Differences in venous clot structures between hemophilic mice treated with emicizumab
Sefiane T; Maynadié H; Ettingshausen CE; Muczynski V; Heiligenstein X; Dumont J; Christophe OD; Denis CV; Casari C; Lenting PJ
Haematologica; 2024 Jun; 109(6):1836-1848. PubMed ID: 38058210
[TBL] [Abstract][Full Text] [Related]
30. High levels of factor VIII activity in patients with acquired hemophilia A in remission are associated with unusually low coagulation potentials.
Shibasaki F; Takeyama M; Ogiwara K; Furukawa S; Nakajima Y; Shimonishi N; Nogami K
Int J Hematol; 2023 May; 117(5):669-677. PubMed ID: 36607560
[TBL] [Abstract][Full Text] [Related]
31. Effect of emicizumab-neutralizing antibodies on activated partial thromboplastin time-based clotting time test results in patients treated with emicizumab.
Novembrino C; Boscolo-Anzoletti M; Galbiati E; Shinohara S; Peyvandi F
Res Pract Thromb Haemost; 2023 Nov; 7(8):102260. PubMed ID: 38193066
[TBL] [Abstract][Full Text] [Related]
32. Two pediatric cases of severe hemophilia A in which emicizumab prophylaxis failed to prevent traumatic extra-articular hemorrhage.
Yamada Y; Nakajima Y; Ohara A; Wakita E; Shimizu K; Shimonishi N; Furukawa S; Ogiwara K; Takeyama M; Nogami K
Int J Hematol; 2023 Apr; 117(4):607-612. PubMed ID: 36370317
[TBL] [Abstract][Full Text] [Related]
33. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada.
Yu JK; Wong WWL; Keepanasseril A; Iorio A; Edginton AN
Haemophilia; 2023 Mar; 29(2):488-497. PubMed ID: 36528890
[TBL] [Abstract][Full Text] [Related]
34. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A.
Shima M; Amano K; Ogawa Y; Yoneyama K; Ozaki R; Kobayashi R; Sakaida E; Saito M; Okamura T; Ito T; Hattori N; Higasa S; Suzuki N; Seki Y; Nogami K
J Thromb Haemost; 2023 Mar; 21(3):534-545. PubMed ID: 36696195
[TBL] [Abstract][Full Text] [Related]
35. Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors.
Escobar M; Agrawal N; Chatterjee S; Bhattacharya S; Caicedo J; Bullano M; Schultz BG
J Med Econ; 2023; 26(1):574-580. PubMed ID: 36989380
[TBL] [Abstract][Full Text] [Related]
36. [Surgery in patients with severe or inhibitory hemophilia A under prevention injection of emicizumab].
Shutov SA; Zozulya NI; Novikov VA; Shutova NA; Glebova AI; Kitsenko EA
Khirurgiia (Mosk); 2023; (5):72-83. PubMed ID: 37186654
[TBL] [Abstract][Full Text] [Related]
37. A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?
Valentino LA; Ozelo MC; Herzog RW; Key NS; Pishko AM; Ragni MV; Samelson-Jones BJ; Lillicrap D
J Thromb Haemost; 2023 Nov; 21(11):3033-3044. PubMed ID: 37225021
[TBL] [Abstract][Full Text] [Related]
38. Sensitive Measurement of Clinically Relevant Factor VIII Levels in Thrombin Generation Assays Requires Presence of Factor XIa.
van de Berg TW; Beckers EAM; Heubel-Moenen FCJI; Henskens YMC; Thomassen MCLGD; Hackeng TM
Thromb Haemost; 2023 Nov; 123(11):1034-1041. PubMed ID: 37236229
[TBL] [Abstract][Full Text] [Related]
39. [Spontaneous disappearance of the inhibitor during emicizumab therapy in a patient with mild hemophilia A].
Matsumoto A; Ogawa Y; Uchiyama Y; Ishikawa T; Naito C; Kobayashi N; Miyazawa Y; Ishizaki T; Inoue M; Moteki Y; Kitazawa S; Murakami M; Matsumoto N; Handa H
Rinsho Ketsueki; 2022; 63(10):1392-1396. PubMed ID: 36351645
[TBL] [Abstract][Full Text] [Related]
40. Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab.
Valls R; Wagg J; Paz-Priel I; Man G; Artigas L; Jaccard G; Coma M; Schmitt C
Sci Rep; 2023 Jun; 13(1):10078. PubMed ID: 37344529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
